Robert J Glynn

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 31

Top Topics

Acute Myocardial Infarction

Electronic Health Record

Ejection Fraction

Top Venues

Pharmacoepidemiology and drug safety

Arteriosclerosis, thrombosis, and vascular biology

Journal of the American Heart Association

Clinical epidemiology

This page only lists publications with an associated author ORCID identifier.

Publications

Rosangela Akemi Hoshi, Mona Alotaibi, Yanyan Liu, Jeramie D Watrous, Paul M Ridker, Robert J Glynn, Charles Nicholas Serhan, Heike Luttmann-Gibson, M Vinayaga Moorthy, Mohit Jain, Demler V Olga, Samia Mora
One-Year Effects of High-Intensity Statin on Bioactive Lipids: Findings From the JUPITER Trial. Arteriosclerosis, thrombosis, and vascular biology 44 (7) (2024)
Nazleen F Khan, Katsiaryna Bykov, Robert J Glynn, Seanna M Vine, Joshua J Gagne
Comparative risk of opioid overdose in patients who initiated antibiotics for urinary tract infection while on long-term opioid therapy. American journal of epidemiology (2024)
Rosangela Akemi Hoshi, Mona Alotaibi, Yanyan Liu, Jeramie D Watrous, Paul M Ridker, Robert J Glynn, Charles Nicholas Serhan, Heike Luttmann-Gibson, M Vinayaga Moorthy, Mohit Jain, Demler V Olga, Samia Mora
One-Year Effects of High-Intensity Statin on Bioactive Lipids: Findings From the JUPITER Trial. Arteriosclerosis, thrombosis, and vascular biology 44 (7) (2024)
Rosangela Akemi Hoshi, Mona Alotaibi, Yanyan Liu, Jeramie D Watrous, Paul M Ridker, Robert J Glynn, Charles Nicholas Serhan, Heike Luttmann-Gibson, M Vinayaga Moorthy, Mohit Jain, Demler V Olga, Samia Mora
One-Year Effects of High-Intensity Statin on Bioactive Lipids: Findings From the JUPITER Trial. Arteriosclerosis, thrombosis, and vascular biology 44 (7) (2024)
Phyo Than Htoo, Helen Tesfaye, Sebastian G Schneeweiss, Deborah J Wexler, Brendan M Everett, Robert J Glynn, Niklas Schmedt, Lisette Koeneman, Anouk Déruaz-Luyet, Julie M Paik, Elisabetta Patorno
Effectiveness and safety of empagliflozin: final results from the EMPRISE study. Diabetologia (2024)
Nazleen F Khan, Katsiaryna Bykov, Jeffrey N Katz, Robert J Glynn, Seanna M Vine, Seoyoung C Kim
Risk of fall or fracture with concomitant use of prescription opioids and other medications in osteoarthritis patients. Pharmacoepidemiology and drug safety 33 (3) (2024)
Nazleen F Khan, Katsiaryna Bykov, Jeffrey N Katz, Robert J Glynn, Seanna M Vine, Seoyoung C Kim
Risk of fall or fracture with concomitant use of prescription opioids and other medications in osteoarthritis patients. Pharmacoepidemiology and drug safety 33 (3) (2024)
Sarah R Preis, Peter T Evans, Kueiyu Joshua Lin, Ashvin N Pande, Alexander Cervone, Su Been Lee, Susan C Cheng, Theodore N Tsacogianis, Robert J Glynn, Dae Hyun Kim
Frailty and Clinical Outcomes of Ticagrelor Versus Clopidogrel in Older Adults With Acute Myocardial Infarction. Journal of the American Heart Association 13 (15) (2024)
Phyo Than Htoo, Helen Tesfaye, Sebastian G Schneeweiss, Deborah J Wexler, Brendan M Everett, Robert J Glynn, Niklas Schmedt, Lisette Koeneman, Anouk Déruaz-Luyet, Julie M Paik, Elisabetta Patorno
Effectiveness and safety of empagliflozin: final results from the EMPRISE study. Diabetologia 67 (7) (2024)
Sarah R Preis, Peter T Evans, Kueiyu Joshua Lin, Ashvin N Pande, Alexander Cervone, Su Been Lee, Susan C Cheng, Theodore N Tsacogianis, Robert J Glynn, Dae Hyun Kim
Frailty and Clinical Outcomes of Ticagrelor Versus Clopidogrel in Older Adults With Acute Myocardial Infarction. Journal of the American Heart Association 13 (15) (2024)
Rosangela Akemi Hoshi, Mona Alotaibi, Yanyan Liu, Jeramie D Watrous, Paul M Ridker, Robert J Glynn, Charles Nicholas Serhan, Heike Luttmann-Gibson, M Vinayaga Moorthy, Mohit Jain, Demler V Olga, Samia Mora
One-Year Effects of High-Intensity Statin on Bioactive Lipids: Findings From the JUPITER Trial. Arteriosclerosis, thrombosis, and vascular biology (2024)
Nazleen F Khan, Katsiaryna Bykov, Jeffrey N Katz, Robert J Glynn, Seanna M Vine, Seoyoung C Kim
Risk of fall or fracture with concomitant use of prescription opioids and other medications in osteoarthritis patients. Pharmacoepidemiology and drug safety 33 (3) (2024)
Rosangela Akemi Hoshi, Mona Alotaibi, Yanyan Liu, Jeramie D Watrous, Paul M Ridker, Robert J Glynn, Charles Nicholas Serhan, Heike Luttmann-Gibson, M Vinayaga Moorthy, Mohit Jain, Demler V Olga, Samia Mora
One-Year Effects of High-Intensity Statin on Bioactive Lipids: Findings From the JUPITER Trial. Arteriosclerosis, thrombosis, and vascular biology (2024)
Nazleen F Khan, Katsiaryna Bykov, Jeffrey N Katz, Robert J Glynn, Seanna M Vine, Seoyoung C Kim
Risk of fall or fracture with concomitant use of prescription opioids and other medications in osteoarthritis patients. Pharmacoepidemiology and drug safety 33 (3) (2024)
Sarah R Preis, Peter T Evans, Kueiyu Joshua Lin, Ashvin N Pande, Alexander Cervone, Su Been Lee, Susan C Cheng, Theodore N Tsacogianis, Robert J Glynn, Dae Hyun Kim
Frailty and Clinical Outcomes of Ticagrelor Versus Clopidogrel in Older Adults With Acute Myocardial Infarction. Journal of the American Heart Association (2024)
Phyo Than Htoo, Robert J Glynn, Shirley V Wang, Julie M Paik, Sebastian G Schneeweiss, Alexander Muir Walker, Elisabetta Patorno
Stratified analysis in comparative effectiveness studies that emulate randomized trials. Pharmacoepidemiology and drug safety (2023)
Yi Li, Maya B Mathur, Daniel H Solomon, Paul M Ridker, Robert J Glynn, Kazuki Yoshida
Effect Measure Modification by Covariates in Mediation: Extending Regression-based Causal Mediation Analysis. Epidemiology (Cambridge, Mass.) 34 (5) (2023)
HoJin Shin, Sebastian G Schneeweiss, Robert J Glynn, Elisabetta Patorno
Evolving channeling in prescribing SGLT-2 inhibitors as first-line treatment for type 2 diabetes. Pharmacoepidemiology and drug safety 31 (5) (2022)
Bernard A Rosner, Robert J Glynn, A Heather Eliassen, Susan E Hankinson, Rulla M Tamimi, Wendy Y Chen, Michelle D Holmes, Yi Mu, Cheng Peng, Debbie L Bennett, Walter Churchill Willett, Shelley T Tworoger
A Multi-State Survival Model for Time to Breast Cancer Mortality among a Cohort of Initially Disease-Free Women. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 31 (8) (2022)
HoJin Shin, Sebastian G Schneeweiss, Robert J Glynn, Elisabetta Patorno
Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin : A Cohort Study. Annals of internal medicine 175 (7) (2022)
John G Connolly, Robert J Glynn, Sebastian Schneeweiss, Joshua J Gagne
Improving measurement of binary covariates in claims data: A simulation study. Pharmacoepidemiology and drug safety 29 (9) (2020)
Moa P Lee, Robert J Glynn, Sebastian G Schneeweiss, Kueiyu Joshua Lin, Elisabetta Patorno, Julie Barberio, Raisa Levin, Thomas Evers, Shirley V Wang, Rishi J Desai
Risk Factors for Heart Failure with Preserved or Reduced Ejection Fraction Among Medicare Beneficiaries: Application of Competing Risks Analysis and Gradient Boosted Model. Clinical epidemiology 12 (2020)
Kueiyu Joshua Lin, Gary E Rosenthal, Shawn N Murphy, Kenneth D Mandl, Yinzhu Jin, Robert J Glynn, Sebastian Schneeweiss
External Validation of an Algorithm to Identify Patients with High Data-Completeness in Electronic Health Records for Comparative Effectiveness Research. Clinical epidemiology 12 (2020)
John G Connolly, Sebastian Schneeweiss, Robert J Glynn, Joshua J Gagne
Non-Vitamin K Antagonist Oral Anticoagulants and Angioedema: A Cohort and Case-Crossover Study. Drug safety 42 (11) (2020)
Robert J Glynn, Mark Lunt, Kenneth J Rothman, Charles Poole, Sebastian Schneeweiss, Til Stürmer
Comparison of alternative approaches to trim subjects in the tails of the propensity score distribution. Pharmacoepidemiology and drug safety 28 (10) (2019)
Kazuki Yoshida, Daniel H Solomon, Sebastien J-P A Haneuse, Seoyoung C Kim, Elisabetta Patorno, Sara K Tedeschi, Houchen Lyu, Sonia Hernández-Díaz, Robert J Glynn
A tool for empirical equipoise assessment in multigroup comparative effectiveness research. Pharmacoepidemiology and drug safety 28 (7) (2019)
John G Connolly, Sebastian Schneeweiss, Robert J Glynn, Joshua J Gagne
Quantifying bias reduction with fixed-duration versus all-available covariate assessment periods. Pharmacoepidemiology and drug safety 28 (5) (2019)
Shirley V Wang, Martin Kulldorff, Robert J Glynn, Joshua J Gagne, Jesper Hallas, Kenneth J Rothman, Sebastian G Schneeweiss, Alexander Muir Walker
Reuse of data sources to evaluate drug safety signals: When is it appropriate? Pharmacoepidemiology and drug safety 27 (6) (2018)
Mitchell M Conover, Til Stürmer, Charles Poole, Robert J Glynn, Ross J Simpson, Virginia Pate, Michele Jonsson Funk
Classifying medical histories in US Medicare beneficiaries using fixed vs all-available look-back approaches. Pharmacoepidemiology and drug safety 27 (7) (2018)
Tracy L Kinsey, Til Stürmer, Charles Poole, Kenneth J Rothman, Robert J Glynn
Changing predictors of statin initiation in US women over two decades. Pharmacoepidemiology and drug safety 28 (3) (2018)
Robert J Glynn, Graham A Colditz, Rulla M Tamimi, Wendy Y Chen, Susan E Hankinson, Walter W Willett, Bernard Rosner
Extensions of the Rosner-Colditz breast cancer prediction model to include older women and type-specific predicted risk. Breast cancer research and treatment 165 (1) (2017)